Ruesch Center Support for the Cure of GI Cancers

This campaign ends on June 30 at 11:59PM EDT

Join The Ruesch Center for the Cure of Gastrointestinal Cancers!

Gastrointestinal (GI) cancers are the most common and the most fatal of all cancers, yet they continue to be dramatically underfunded.

At The Ruesch Center, our researchers are performing ground-breaking studies that could lead to the next generation of life-saving cancer treatments, such as:

  • Dr. Benjamin Weinberg, M.D., who is examining whether there is a link between the spike in colorectal cancer in young patients and bacteria living in the gut. Gut bacteria are vital to our survival, but certain types of bacteria (likely linked to the Western diet) might also be associated with colorectal cancer in younger adults. By illuminating the link between gut bacteria and colorectal cancer, Dr. Weinberg hopes to gain more insight into the prevention or treatment of this disease. Dr. Weinberg is also working with Dr. Keith Unger, a Georgetown radiation oncology specialist, on the combination of proton therapy, chemotherapy, and surgery in the treatment of patients with rectal cancer.
  • Dr. Marcus Noel, M.D., who has a significant interest in novel drug development for patients with pancreatic cancer. Still relatively new to Georgetown, Marcus has two clinical trials in the pipeline, both studying the addition to chemotherapy of Eryaspase, an agent added to red blood cells that starves pancreatic tumors and stops them growing. One study will treat patients with pancreatic cancer in the front line with Eryaspase + FOLFIRINOX, and the other will add Eryaspase to later lines of chemotherapy for patients who have not responded to standard first-line therapy.
  • Dr. Ruth He, M.D., Ph.D., whose passion is the prevention and treatment of liver and bile-duct cancers. She is highly focused on the use of immunotherapy combinations to fight hepatocellular carcinoma and cholangiocarcinoma. She was a co-investigator in the IMbrave study that led to the approval of atezolizumab and bevacizumab in the front line against HCC.

Please help us keep the momentum going with a generous gift today!

This year more than 300,000 Americans will be diagnosed with GI cancer, and more than 50% will die within five years. The highest-incidence GI cancers include colorectal cancers, pancreatic cancers, liver and biliary cancers, gastric cancers, and esophageal cancers. The Ruesch Center is a global pioneer, unmatched by any other GI cancer program. Relentlessly fighting a smarter war against GI cancer by partnering with patients based on their unique needs, the Ruesch Center is carrying out cutting-edge, innovative research and providing the highest standard of care and individualized cures. We need your support to continue this life-saving work. 

Questions?

Please Contact: Kristi Augenblick Associate Director of Development ka756@georgetown.edu | 202-687-2464

If you prefer to give via cash/check please make payable to 'RUESCH CENTER CURE FOR GI CANCERS' and mail to: Georgetown University Gift Administration, 3300 Whitehaven St NW, Suite 3000 Washington, DC 20007

Updates

 
loading

Donor affiliations


40% Friends

Show Friends

Donor list

Don and Debby Tracy
David & Sheila Bernstein
Jacob Barton
Simon
Elissa Levan
Become an Advocate and be recognized for your impact!

Sign up or Log in to get started


SHARE WITH YOUR NETWORK

Share the campaign to track the number of clicks, gifts, and dollars you generate (Note: If you share without signing up or logging in, your impact will be counted as a Community Advocate).


INSPIRE YOUR FRIENDS AND PEERS

Encourage others to give with a Matching Gift or Challenge.


TELL YOUR STORY

Create a Personal Plea video encouraging others to join you in supporting the campaign.


loading
No Active Matches
No Active Challenges